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§ Update the epidemiology of Zika	  virus disease in the Americas
and the United States
§ Review the objecNves and phased approach to Zika	  virus
surveillance in the United States
§ Discuss strategies to idenNfy local mosquito-­‐borne transmission




Zika Virus in the Americas
§ In May 2015, the first	  locally-­‐acquired cases in the Americas
were reported in Brazil
§ As of June 2, 2016, local transmission reported in 39 countries
or territories in the Americas
§ Further spread to other countries in the region is likely
Suspected and Confirmed Locally TransmiMed Zika Virus Disease Cases




Colombia	   87,355 (21%)
Venezuela	   31,576 (8%)
MarNnique 26,662 (6%)
Honduras 21,069 (5%)
Puerto Rico 11,705 (3%)
El Salvador 11,677 (3%)
*13% of cases are lab-­‐confirmed
Suspected and Confirmed Locally TransmiMed Zika Virus Disease Cases







N=415,993 suspected and confirmed cases
Suspected and Confirmed Locally TransmiMed Zika Virus Disease Cases





Zika Virus in the United States
§ Local mosquito-­‐borne transmission of Zika	  virus has not	  been
reported in the conNnental United States
§ In 2011–2014, 11 lab-­‐confirmed Zika	  virus disease cases idenNfied
in travelers returning to the U.S. from areas with local transmission
§ With current	  outbreaks in the Americas, cases among U.S. travelers
have increased substanNally
§ Imported cases may result	  in virus introducNon and local spread in
some areas of United States
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ObjecKves	  of	  Zika Virus	  Surveillance	  in the	  United
States	  
§ IdenNfy and define areas with local mosquito-­‐borne transmission
§ Direct	  prevenNon and control efforts
§ IdenNfy and monitor infecNons in people at risk for poor outcomes
§ QuanNfy and describe disease burden
Zika Virus Surveillance Phases
0. Pre-­‐incident	  preparedness
1. Mosquito season
2. Limited local transmission in one geographic area	  
3. Widespread local transmission in one geographic area	  







Phase	  0. Pre-­‐incident Preparedness	  
§ Assess risk areas, populaNons, and Nming
§ Educate healthcare providers and local public health officials
§ Establish public health laboratory tesNng and surge capacity
§ Discuss tesNng capacity and reporNng with commercial laboratories
§ Develop response plan with mosquito control districts






Assessing Risk	  of Local Mosquito-­‐borne Transmission
§ Aedes aegyp, or Aedes albopictus present	  and acNve in area	  
§ Prior local transmission of dengue or chikungunya	  viruses
§ Returning travelers with Zika	  virus infecNon
§ Local populaNon density and household infrastructure











Phase 1. Mosquito Season
§ InvesNgate and test	  suspected cases, and assess exposures
– Recent	  travel
– Sexual transmission
– Blood transfusion/organ transplantaNon
– Local mosquito-­‐borne
§ Respond to confirmed travel-­‐associated cases
– Vector evaluaNon and control around home
– Limit	  subsequent	  mosquito exposures
– Educate about	  sexual transmission and blood donaNon risks







Who to Test for Zika Virus InfecKon
§ PaNent	  with fever, rash, arthralgia, or conjuncNviNs
–	 Onset	  during or within 2 weeks of travel to an area	  with ongoing
transmission, OR	  
– Epidemiologic link to laboratory-­‐confirmed case through verNcal
transmission, sexual contact, or associaNon in Nme and place
§ Offer tesNng to asymptomaNc pregnant	  women
–	 History of travel to an area	  with ongoing transmission, OR	  
–	 Sexual contact	  with a partner who had symptoms of Zika	  virus disease








ReporKng Zika Virus Diseases Cases
§ Zika	  virus disease and congenital infecNon are naNonally noNfiable
– CSTE approved interim case definiNons in February 2016*	  
– Revised definiNons will be considered at June meeNng
§ Healthcare providers encouraged to report	  suspected cases to their state
or local health department	  
§ State health departments should report	  laboratory-­‐confirmed cases to
CDC according to CSTE case definiNons
– Pregnant	  women and congenital infecNons followed through registry
§ Timely reporNng allows health departments to assess and reduce the risk







Surveillance Strategies	  to IdenKfy	  Possible Local	  Transmission
during Mosquito Season
§ Survey household members and neighbors of travel-­‐associated cases
§ Blood donor	  screening	  
§ InvesNgaNon of unusual clusters of rash illness
§ Expanded tesNng for people with no known exposure but	  more
specific constellaNon of clinical findings






Phase 2. Limited Local Mosquito-­‐borne Transmission
§ Case invesNgaNon to determine most	  likely place of
exposure and whether cases are related
§ AcNve surveillance to idenNfy addiNonal cases and
define the geographic scope of the outbreak
§ Perform vector assessments and control








Surveillance Strategies to IdenKfy AddiKonal Cases and
Define the Geographic Scope of the Outbreak	  
§ Survey household members and neighbors (150-­‐yard radius)
§ NoNfy local healthcare providers and laboratories
§ Syndromic surveillance for increased febrile or rash illness
§ Laboratory-­‐based surveillance for Zika	  or other arboviruses
§ Community outreach to increase awareness







Phase 3. Widespread Local Transmission in One Area
§ Case invesNgaNons to idenNfy foci and target	  control
§ Determine if addiNonal cases likely represent	  single
transmission chain or separate occurrences
§ Expand acNve surveillance acNviNes to further define
size and scope of the outbreak
§ Pregnant	  women screening and monitoring
§ Blood donor screening (if not	  previously implemented)
 
Phase 4. Widespread Local Transmission in MulKple Areas
§ Scale up surveillance and control acNviNes based on






§ IdenNfy local transmission and infecNons in people at risk for
poor outcomes
§ Define affected area	  and populaNons to direct	  prevenNon and
control efforts
§ Phased response based size, scope, area, and Nming of the
outbreak
§ Coordinate efforts between state/local health departments,
mosquito control districts, commercial laboratories, blood






QuesKons for State and Local Health Departments
§ What	  is the risk of local mosquito-­‐borne Zika	  virus transmission
in your jurisdicNon?	  

§ Do you have a Zika	  virus surveillance and response plan?
§ Do your lab have capacity to test	  for Zika	  and dengue viruses?
§ Have you coordinated with local mosquito control districts and
blood collecNon agencies?
§ Do you have adequate capacity and resources for surveillance
and control of Aedes species mosquitoes?
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